GPNMB is a glycoprotein observed upon tissue damage and inflammation and is associated with astrocytes, microglia, and macrophages. Gene variations in GPNMB are linked with Parkinson's disease (PD) risk, and changes in protein levels of GPNMB have been found in lysosomal storage disorders, including Gaucher's disease with glucocerebrosidase (GCase) deficiency. In the current study, GPNMB increases were seen in the substantia nigra (SN) of PD patients compared to age-matched controls. Such PD patients have a decrease in GCase activity and corresponding elevation of glycosphingolipids in the SN (Rocha et al., 2015a). Interestingly, transgenic mice modelling synucleinopathy did not show GPNMB elevations or altered GCase activity levels compared to wildtype mice. However, upon CBE-induced GCase lysosomal dysfunction with elevated glycosphingolipids in wildtype mice, there were similar changes in GPNMB levels in the brain as seen in PD patient brains. These results indicate that GPNMB levels do not depend on alpha-synuclein load per se but relate directly to the lipidopathy changes induced by CBE-mediated GCase inhibition. The experimental modelling of elevating glycolipids resulted in GPNMB elevations with glial activation in several brain regions in mice. This is the first demonstration of region-specific elevations of GPNMB protein in Parkinson's disease. The presence of GPNMB in PD patient substantia nigra, the induction of GPNMB after experimental glycosphingolipid increases, but not with pure alpha-synucleinopathy, point towards the potential for primary lipid-induced degeneration in PD.
Introduction
Recently a large genome-wide association study of Parkinson's disease (PD) patients identified several novel genetic variants linked to the function of the autophagic-lysosomal pathway, with polymorphisms in the GPNMB gene found to associate with idiopathic PD (Kumaran and Cookson, 2015) . Studies have identified transcriptional changes in GPNMB in rodent models of both PD and Alzheimer's disease (Kanaan et al., 2015; Srinivasan et al., 2016) , and a recent report based on data mining techniques identified elevations of GPNMB mRNA in the substantia nigra of PD patients (Neal et al., 2018) . Furthermore, GPNMB protein levels are elevated and correlate with disease severity and progression in lysosomal storage disorders (Zigdon et al., 2015; Kramer et al., 2016; Murugesan et al., 2018) .
The relationship between lysosomal storage disorders (LSDs) and Parkinson's disease (PD) is becoming apparent through evidence of glycosphingolipid dysregulation and lysosomal dysfunction in the pathophysiology of PD. In fact, many of the genetic factors responsible for familial PD play a role in the autophagy-lysosomal pathway (Gan-Or et al., 2015) . Haplo-insufficiency due to mutations in the lysosomal hydrolase glucocerebrosidase (GCase) is one of the largest genetic risk factors for the development of PD (Sidransky et al., 2009; Sidransky and Lopez, 2012) . Studies have demonstrated that GCase activity is decreased in the substantia nigra (SN) of sporadic PD patients (Gegg et al., 2012; Rocha et al., 2015a) as well as in normal aging (Rocha et al., 2015a) , and has been associated with driving alpha-synuclein pathology (Mazzulli et al., 2011; Murphy et al., 2014) . Aging is the largest risk factor for PD and cellular changes observed in normal aging may be mirrored in neurodegenerative disorders, albeit at an accelerated rate (Collier et al., 2011 (Collier et al., , 2017 . Lysosomal dysfunction plays an important role in driving the aging phenotype, and is implicated in many agerelated disorders (Carmona-Gutierrez et al., 2016) . The majority of LSDs typically manifest in early infancy or childhood (Nixon et al., 2008) , which may reflect how severe and complete lysosomal dysfunction leads to early onset of disease in children, whereas progressive lysosomal dysfunction with minor lipid changes, as observed in PD, manifests as pathogenic only when compounded with aging.
The neuroinflammatory system also plays an important role in 
